Table 1. Patients characteristics.
| Median | [range] | Number | (%) | ||
| Age (yr) | 60.5 | [34–86] | |||
| Menstruation status | Premenopause | 39 | (28%) | ||
| Postmenopause | 101 | (72%) | |||
| Surgical procedure | Mastectomy | 39 | (28%) | ||
| Breast-conserving surgery | 101 | (72%) | |||
| Tumor size (cm) | 1.7 | [0.5–5.3] | |||
| ER positivity proportion (%) | 90 | [15–95] | |||
| PR positivity proportion (%) | 60 | [0–95] | |||
| Lymphovascular invasion | Negative | 37 | (27%) | ||
| Positive | 101 | (72%) | |||
| Unkown | 2 | (1%) | |||
| Nuclear grade | Grade 1 | 52 | (37%) | ||
| Grade 2 | 54 | (39%) | |||
| Unkown | 34 | 34 (24%) | |||
| Ki67 | < 14% | 18 | (13%) | ||
| Unknown | 122 | (87%) | |||
| Lymph node metastasis status | Negative | 103 | (74%) | ||
| Positive | 37 | (26%) | |||
| Lymph node metastasis number* | 2 | [1–18] | |||
*Number in 37 positive cases.
ER, estrogen receptor; PR, progesterone receptor.